Pfizer - zu Unrecht im Keller
Seite 15 von 198 Neuester Beitrag: 06.09.24 21:20 | ||||
Eröffnet am: | 21.10.04 12:39 | von: Anti Lemmin. | Anzahl Beiträge: | 5.925 |
Neuester Beitrag: | 06.09.24 21:20 | von: Zitherholz | Leser gesamt: | 1.309.084 |
Forum: | Börse | Leser heute: | 520 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 12 | 13 | 14 | | 16 | 17 | 18 | ... 198 > |
Bei Pfizer warte ich auf einen Rückschlag unter 26 USD, der evtl. nach den Zahlen kommt.
Es gibt zurzeit aber nicht nur Horrormeldungen, sondern auch Lichtblicke wie gestern die Zahlen von Texas Instruments und Logitech. Das wird den Tech-Sektor beflügeln. Gestern habe ich im Tief gekauft: Intel, AMD, Cisco, Sun, Lucent, Calpine (kalifornischer Energieerzeuger), Ford, AIG, Commerce Bancorp (CBH), THC, Delta Airlines (DAL) u. a. Falls die Indizes nicht nach oben drehen, würde ich aber bald wieder rausgehen. Außerdem hab ich für 1,3025 wieder Dollars gekauft.
By Michael Baron, MarketWatch
Last Update: 7:49 AM ET April 19, 2005
NEW YORK (MarketWatch) - Pfizer posted an adjusted profit early Tuesday that topped Wall Street's consensus view by a penny.
The Dow component also detailed the impact of its decision to suspend sales of its Bextra arthritis pain treatment on fiscal 2005 results and said it expects to return to double-digit earnings growth in fiscal 2006.
Before the opening bell, Pfizer (PFE: news, chart, profile) reported first-quarter earnings of $301 million, or 4 cents per share, down from its year-ago profit of $2.33 billion, or 30 cents per share.
The results for the latest quarter, however, included a number of items, including a charge of $622 million, or 8 cents per share, related to purchase accounting for acquisitions, $766 million in charges related to the suspension of sales of Bextra, and $2.189 billion in tax expenses related to repatriated earnings, among others.
Excluding items, the New York drug giant earned $4 billion, or 54 cents per share, in the March period. Revenue rose 5 percent in the latest three months to $13.09 billion.
The average estimate of analysts was for earnings of 53 cents per share in the quarter on revenue of $12.52 billion.
"Several factors affected first-quarter results, including several unique to the quarter," said Alan Levin, chief financial officer. "Revenue growth benefited from strong performances of many major in-line medicines, as well as three additional days in our fiscal calendar compared to the first quarter of 2004."
Sales of Lipitor, the company's blockbuster cholesterol drug, showed the most growth, rising 23% in the quarter to $3.08 billion from $2.5 billion in the same period a year earlier.
Looking ahead, Pfizer forecast adjusted earnings of $1.98 per share for 2005. Wall Street's current consensus estimate is for a profit of $1.97 per share for the year. The company estimates the suspension of sales of Bextra will reduce adjusted and reported earnings by 5 cents per share in fiscal 2005.
The stock closed Monday at $27.60, down 11 cents.
Dies ist im Prinzip positiv. Der Markt neigt im Moment allerdings dazu, auch gute Zahlen abzustrafen: Sie Apple, Commerce Bancorp u. a.
Mir soll es Recht sein. Nur so bekomme ich bei Pfizer noch einmal eine Einstiegsgelegenheit zum Schnäppchenpreis - am liebsten unter 26 Dollar.
NEW YORK TIMES
April 20, 2005
Pfizer Earnings Plunge 87% on Painkillers' Problems
By STEPHANIE SAUL
The world's largest drug maker, Pfizer, reported sharply lower first-quarter earnings yesterday, partly because of the fallout from its controversial cox-2 inhibitor painkillers, Bextra and Celebrex.
The company took a $766 million charge related to the withdrawal of Bextra from the market and reported lower sales of its other arthritis drug, Celebrex.
A rival health care company, Johnson & Johnson, reported a double-digit earnings increase on record sales yesterday, driven largely by strong growth in medical devices. Johnson & Johnson also increased its earnings guidance for the year.
Pfizer earned $301 million, or 4 cents a share, a drop of 87 percent from the $2.33 billion, or 31 cents a share, it earned in the first quarter of 2004.
Pfizer, which is based in New York, said that in addition to its cox-2 problems, results this year would be affected by the loss of United States exclusivity on four major drugs: Diflucan, Neurontin and Accupril during 2004 and Zithromax in 2005.
But the picture was not all gloomy, thanks largely to continuing double-digit growth of the cholesterol-lowering drug Lipitor, one of the world's top-selling medicines. Sales of the drug increased 23 percent, to $3.08 billion in the first quarter. Pfizer's overall sales rose nearly 5 percent to $13.09 billion.
Without one-time charges, Pfizer's earnings were $4 billion, or 54 cents a share, exceeding Wall Street expectations by one penny.
In a statement, Pfizer's chief executive, Henry A. McKinnell Jr., characterized the company's performance as steady, but he said 2005 would be a transitional year. Dr. McKinnell said the company's size, as well as the breadth of its portfolio and pipeline, would permit it to "marshal and refocus resources."
Bextra was withdrawn from the market early this month, but negative publicity surrounding the cox-2 inhibitors had already led to a sales decline in the first quarter. Bextra revenue dropped to $56 million, 79 percent less than the $270 million in the first quarter of 2004. The Food and Drug Administration asked Pfizer to stop selling Bextra because of evidence linking it to a rare but serious skin disorder. Pfizer said it disagreed with the F.D.A.'s risk-benefit analysis of Bextra and was meeting with regulators in an effort to resume sales of the drug.
Celebrex remains on the market, but its sales were down to $411 million, the company said, as consumers and physicians focused on reports about heart risks associated with drugs in the cox-2 class. In the first quarter of 2004, Pfizer sold $769 million worth of Celebrex.
Johnson & Johnson's record sales of $12.83 billion, up 11 percent, reflected stronger sales of medical devices as well as continued growth in some of its pharmaceutical products. Net income was $2.93 billion, or 97 cents a share, compared with $2.49 billion, or 83 cents, a year earlier, an increase of 17.7 percent.
Sales of Remicade, which is used to treat autoimmune disorders, were up 22 percent, to $501 million. Sales of the antipsychotic drug Risperdal also increased, by 16 percent, to $844 million. Revenue from the epilepsy drug Topamax increased 24 percent, to $406 million, partly because it has been approved to treat migraines.
The company, based in New Brunswick, N.J., said generic competition hurt sales for some big drugs, including contraceptives and the painkiller patch Duragesic.
The company also said that it was talking with the F.D.A. about revised labeling for Natrecor, an intravenous drug that is used to treat severe heart failure. Articles in the medical publications Circulation and The Journal of the American Medical Association have raised questions about the drug's safety.
Novartis-Medikament kann töten
Quelle: AP
20. April 2005 08:22
Die US-Gesundheitsbehörde FDA und Novartis haben vor gefährlichen Nebenwirkungen eines Epilepsie-Medikaments des Schweizer Pharmakonzerns gewarnt.
In einem am Dienstag auf der Webseite der FDA veröffentlichten Schreiben von Novartis heisst es, das Medikament Trileptal könne lebensbedrohende Hautreaktionen auslösen. Eine Novartis-Sprecherin in den USA ergänzte auf Anfrage, das Unternehmen habe in der Zeit vom Februar 2000 bis zum August 2004 19 Berichte über ernsthafte Hautreaktionen erhalten. Darunter sei ein Todesfall gewesen. Trileptal ist gemäss der Sprecherin an mehr als eine Million Patienten verschrieben worden. Das Medikament ist für die Behandlung von Erwachsenen sowie von Kindern ab vier Jahren zugelassen. Novartis ergänzte nach eigenen Angaben den Beipackzettel mit der Warnung vor den möglichen Hautreaktionen.
"Die Pharmaspekulation ist ein weltweites Thema. Zu den ROCHE-Zahlen
habe ich gestern schon Stellung genommen. Die Erholung der anderen wie
NOVARTIS oder SANOFI geht also weiter.
PFIZER nannte gestern enttäuschende Zahlen, doch das war offenbar schon
eingepreist. PFIZER liegt sowohl unter der eigenen Prognose wie unter der
der Analysten. Damit ist aber die Luft auch raus, denn der Kurs fiel nicht,
sondern legte leicht zu. Das ist identisch zu MERCK, die mit gleichen Daten
inzwischen bis auf 84,80 $ anzogen. Die LILLY-Akzente hatte ich gestern be-
schrieben und JOHNSON & JOHNSON übertrifft als einziger alle Erwartungen."
Zu früh gefreut. Wie nach dem NYT-Artikel (Posting 357) zu erwarten war, gaben Pfizer heute von 28 auf bislang 26,96 USD ab. Ich bin vor ein paar Wochen bei 26,48 USD ausgestiegen (zu früh) - und würde am liebsten erst bei Kursen unter 26 wieder einsteigen.
Pfizer bricht Umsatz in Deutschland weg
von Peter Kuchenbuch, Hamburg
Die Umsätze des weltweit meistverkauften Medikaments Sortis brechen in Deutschland infolge der Gesundheitsreform ein. Im ersten Quartal 2005 schrumpften die Verkäufe des Cholesterinsenkers vom US-Hersteller Pfizer im Vergleich zum Vorjahreszeitraum um 68 Prozent auf nur noch 24,16 Mio. Euro.
Das geht aus aktuellen Zahlen der Marktforschungsfirma IMS Health hervor, die der FTD vorliegen. Die IMS-Daten beziehen sich auf die Sortis-Umsätze zu Herstellerabgabepreisen, also den Wert der Ware, bevor sie vom Apotheker an die Patienten abgegeben wird. Im März hat Sortis, das in Märkten wie den USA Lipitor heißt, sogar 74 Prozent seines Umsatzes im Vergleich zum Vorjahresmonat eingebüßt.
Pfizer hatte den Einbruch befürchtet, nachdem zum 1. Januar 2005 das neue Gesundheitsmodernisierungsgesetz (GMG) in Kraft getreten war. Mit der Novelle wurde das patentgeschützte und hochpreisige Sortis in eine Erstattungsgruppe mit günstigeren Nachahmerprodukten aus der gleichen Wirkstoffgruppe gesteckt.
Da Pfizer aber den Sortis-Preis nicht auf das Niveau dieser so genannten Jumbogruppe absenken wollte, müssen Patienten, die weiter Sortis einnehmen wollen, fortan einen Eigenanteil zuzahlen. Laut Pfizer muss ein Kassenpatient mit Zusatzkosten von rund 200 Euro jährlich rechnen.
Während Privatpatienten Pfizer die Treue halten, sind Kassenpatienten abgesprungen. Von 1,5 Millionen gesetzlich versicherten Sortis-Patienten in 2004 seien jetzt nur noch 800.000 übrig, so eine Pfizer-Sprecherin.
Damit fällt Sortis auf den 18. Platz der deutschen Arzneimittelrangliste zurück. Von den Veränderungen profitiert unter anderem der Hersteller des neuen Marktführers bei Cholesterinsenkern. Die Firma Hexal, die das Sortis-Konkurrenzprodukt Simvahexal verkauft, wurde kürzlich von Novartis übernommen und wird derzeit mit Sandoz, der Generika-Tochter des Konzerns, verschmolzen. Die Simvahexal-Umsätze legten im ersten Quartal 2005 gegenüber den ersten drei Monaten 2004 um 40 Prozent auf rund 25 Mio. Euro zu, so IMS. Diese Zahl spiegelt allerdings nicht den wahren Firmenumsatz wider, da Generikahersteller den Apothekern Rabatt-Packungen schenken, die den geldwerten Umsatz mindern.
Bei den gesetzlichen Krankenkassen sackte Sortis in der Gruppe der Cholesterinsenker von einem Marktanteil von über 30 Prozent auf nur noch sieben Prozent ab. Der Marktanteil von Sortis bei den Verordnungen privat Versicherter liegt bei 50 Prozent. "Das ist ein klarer Fall von Zwei-Klassen-Medizin", so die Pfizer-Sprecherin. Sortis hat laut Pfizer therapeutische Vorteile gegenüber anderen Produkten aus der Jumbo-Gruppe. Diese würden nun vielen Patienten nicht mehr ohne weiteres zugute kommen.
Celebrex Gaining Bextra's Prescriptions
05.17.2005, 03:33 PM
It is a silver lining of sorts. Pfizer Inc. arthritis drug Celebrex has been the biggest beneficiary of last month's withdrawal of Bextra, a pain reliever made by the same company. Celebrex has grabbed roughly a third of Bextra's prescriptions while Mobic, a pain reliever marketed by Boehringer Ingelheim GmbH and Abbott Laboratories Inc., has captured around 26 percent.
Pfizer removed Bextra from the market on April 7 at the request of the U.S. Food and Drug Administration, which was concerned about its links to heart attacks and a rare skin condition.
Analysts said the shift to Celebrex is a glimmer of good news for Pfizer, but they note the glory days of the drug are firmly behind it, as doctors have increasingly shifted patients to other prescription medications or over-the-counter products. Safety concerns have contracted the entire market for arthritis drugs, but Celebrex's slide has been deeper than the overall drop.
Celebrex, like Bextra and the also-withdrawn Vioxx from Merck & Co., belong to a class of drugs known as Cox-2 inhibitors. Last year, all were linked to an increased risk of heart attacks. The finding led doctors to prescribe more Mobic, as well as older drugs such ibuprofen and naproxen. But last month, the FDA said all non-steriodal, anti-inflammatory drugs including Celebrex, Mobic, naproxen, and ibuprofen must carry a warning about potential cardiovascular risks.
"The market is in a state of flux," said Dr. Steven Abramson, chairman of rheumatology at New York University-Hospital for Joint Disease. "I don't know where we see the bottom of the market, but there is a real need for these drugs."
In the weeks since Bextra's withdrawal, Abramson said he has switched patients to a variety of drugs including Celebrex, Mobic and naproxen. He said overall, doctors are prescribing lower doses of all the drugs and limiting the time patients take the medications.
While the FDA's decision on Bextra and the other pain relievers created confusion for doctors and patients, it certainly roiled Pfizer. Just two days before it pulled Bextra off the market, Pfizer executives told analysts and journalists it believed it could revitalize sales of both Celebrex and Bextra as part of a strategy to return the company to double-digit growth by next year. It hasn't backed away from that projection. However, the company did lower its after-charges earnings projection for this year to $1.98 from $2 as it took a $766 million charge during the first quarter for halting Bextra sales.
Analysts had noted that Celebrex would pick up some Bextra sales, so the loss wouldn't be a total disaster.
For the week ended May 6, Celebrex picked up 34 percent of Bextra's prescriptions, according to Verispan, which tracks prescription data. A week earlier, it grabbed 32 percent. For the week ended May 6, Celebrex's new prescriptions totaled 228,898, while new prescription reached 92,674 - its best showing in at least three months.
Analyst Jason Napodano said Celebrex was performing better than he imagined but believed the results were likely below but Pfizer's expectations.
"I think 30 percent (of the Bextra prescriptions) would be good," said Napodano, of Zacks Investment Research Inc.
Pfizer wouldn't comment on its projections.
Last year, Celebrex generated $3.3 billion in sales while Bextra revenues totaled $1.3 billion. Bert Hazlett, an analyst at Suntrust Robinson Humphrey, had thought Celebrex sales would total $1.8 billion this year. He lowered his projection after Bextra was withdrawn to $1.75 billion because he felt Celebrex would be hurt in the fallout.
Hazlett was predicting flat sales growth for Celebrex in the next two years but said the gains from Bextra suggest Pfizer may be able to grow revenues. Now he thinks revenues next year could hit $1.825 billion and increase to $1.9 billion in 2007. But he said for Celebrex to get anywhere near its 2004 revenues it would need a host of new studies proving its usefulness in other areas and attesting to its safety.
Shares of Pfizer fell 4 cents to $28.19 in afternoon trading on the New York Stock E
xchange, where they have traded in a 52-week range of $21.99 to $36.60.
05.17.2005, 04:46 PM
It is a silver lining of sorts.
Pfizer Inc. arthritis drug Celebrex has been the biggest beneficiary of last month's withdrawal of Bextra, a pain reliever made by the same company. Celebrex has grabbed roughly a third of Bextra's prescriptions while Mobic, a pain reliever marketed by Boehringer Ingelheim GmbH and Abbott Laboratories Inc., has captured around 26 percent. Pfizer removed Bextra from the market on April 7 at the request of the U.S. Food and Drug Administration, which was concerned about its links to heart attacks and a rare skin condition.
Analysts said the shift to Celebrex is a glimmer of good news for Pfizer, but they note the glory days of the drug are firmly behind it, as doctors have increasingly shifted patients to other prescription medications or over-the-counter products. Safety concerns have contracted the entire market for arthritis drugs, but Celebrex's slide has been deeper than the overall drop.
Celebrex, like Bextra and the also-withdrawn Vioxx from Merck & Co., belong to a class of drugs known as Cox-2 inhibitors. Last year, all were linked to an increased risk of heart attacks. The finding led doctors to prescribe more Mobic, as well as older drugs such ibuprofen and naproxen. But last month, the FDA said all non-steriodal, anti-inflammatory drugs including Celebrex, Mobic, naproxen, and ibuprofen must carry a warning about potential cardiovascular risks.
"The market is in a state of flux," said Dr. Steven Abramson, chairman of rheumatology at New York University-Hospital for Joint Disease. "I don't know where we see the bottom of the market, but there is a real need for these drugs."
In the weeks since Bextra's withdrawal, Abramson said he has switched patients to a variety of drugs including Celebrex, Mobic and naproxen. He said overall, doctors are prescribing lower doses of all the drugs and limiting the time patients take the medications.
While the FDA's decision on Bextra and the other pain relievers created confusion for doctors and patients, it certainly roiled Pfizer. Just two days before it pulled Bextra off the market, Pfizer executives told analysts and journalists it believed it could revitalize sales of both Celebrex and Bextra as part of a strategy to return the company to double-digit growth by next year. It hasn't backed away from that projection. However, the company did lower its after-charges earnings projection for this year to $1.98 from $2 as it took a $766 million charge during the first quarter for halting Bextra sales.
Analysts had noted that Celebrex would pick up some Bextra sales, so the loss wouldn't be a total disaster.
For the week ended May 6, Celebrex picked up 34 percent of Bextra's prescriptions, according to Verispan, which tracks prescription data. A week earlier, it grabbed 32 percent. For the week ended May 6, Celebrex's new prescriptions totaled 228,898, while new prescription reached 92,674 - its best showing in at least three months.
Analyst Jason Napodano said Celebrex was performing better than he imagined but believed the results were likely below but Pfizer's expectations.
"I think 30 percent (of the Bextra prescriptions) would be good," said Napodano, of Zacks Investment Research Inc.
Pfizer wouldn't comment on its projections.
Last year, Celebrex generated $3.3 billion in sales while Bextra revenues totaled $1.3 billion. Bert Hazlett, an analyst at Suntrust Robinson Humphrey, had thought Celebrex sales would total $1.8 billion this year. He lowered his projection after Bextra was withdrawn to $1.75 billion because he felt Celebrex would be hurt in the fallout.
Hazlett was predicting flat sales growth for Celebrex in the next two years but said the gains from Bextra suggest Pfizer may be able to grow revenues. Now he thinks revenues next year could hit $1.825 billion and increase to $1.9 billion in 2007. But he said for Celebrex to get anywhere near its 2004 revenues it would need a host of new studies proving its usefulness in other areas and attesting to its safety.
Shares of Pfizer fell 3 cents to close at $28.20 in Tuesday trading on the New York Stock Exchange, where they have traded in a 52-week range of $21.99 to $36.60.
------------------
FTD 27.5.05
Pfizer-Aktie knickt nach Erblindung von Viagra-Patienten ein
In den USA sorgt eine Studie über Erblindungen von Nutzern des Potenzmittels Viagra für Unruhe. Obwohl bislang keine eindeutigen Hinweise auf einen Zusammenhang entdeckt wurden, gaben die Aktion von Pfizer kräftig nach.
Die US-Arzneimittelbehörde FDA untersucht vereinzelte Berichte über eine Erblindung von Viagra-Nutzern. Bislang gebe es aber keine Hinweise darauf, dass das Potenzmittel Ursache der Erblindung sei, sagte FDA-Sprecherin Susan Cruzan am Freitag in Washington. Die spezielle Art der Blindheit kann bei Männern auftreten, die an Diabetes oder einer Herzerkrankung leiden. Beide Erkrankungen können auch zu Impotenz und damit zur Einnahme von Viagra führen.
In den bislang bekannten Fällen wurde ein Schlaganfall des Auges diagnostiziert, in der Fachsprache Naion (Nonarteric Ischemic Optic Neuropathy) genannt.
Der FDA liegen 42 Berichte über Fälle einer derartigen Erblindung vor, 38 davon traten nach der Einnahme von Viagra, vier nach der Einnahme von Cialis auf. Allein Viagra wird weltweit von mehr als 23 Millionen Männern eingenommen.
Ein Sprecher der Herstellerfirma Pfizer bestätigte, dass Gespräche mit der FDA darüber geführt würden, einen Hinweis auf derartige Fälle im Beipackzettel aufzunehmen. Er sagte aber, dass es keinen Beweis dafür gebe, dass Viagra die Erblindung verursacht habe. Männer, die Viagra nähmen, hätten häufig auch einen hohen Blutdruck und einen hohen Cholesterinspiegel - auch dies gelte als Risikofaktor für eine Erblindung. Zu den häufigsten Nebenwirkungen der Potenzpille zählen laut dem Pharmaunternehmen Kopfschmerzen, Gesichtsröte und Übelkeit. Weniger häufig träten kurzzeitige Blausichtigkeit, eine verschwommene Wahrnehmung oder Lichtempfindlichkeit auf.
Anleger lassen Pfizer-Kurs straucheln
Die Pfizer-Aktie büßte an der Wall Street 2,7 Prozent auf 28,11 $ ein. Händler äußerten die Befürchtung, dass auf Pfizer millionenschwere Schadenersatzforderungen zukämen, wenn sie der Verdacht der FDA bestätige.
Im ersten Quartal hatte Pfizer mit dem Potenzmittel einen Umsatz von 438 Mio. $ erwirtschaftet, ein Plus von fünf Prozent binnen Jahresfrist. Das Mittel steht im Wettbewerb mit den Potenzpillen Cialis von Eli Lilly und Levitra von Bayer.
Die Anlegergemeinde wird in Kuerze zur gleichen Ueberlegung kommen.
Ob $ 26 nochmal erreicht werden, keiner kann's sagen. Ich war auch der
Meinung, bins auch noch, da muesste noch eine 2. Korrektur kommen.
Jedenfalls mit Sell in May and go away war's diesmal ein Griff daneben.
Gruesse Jing
NYT:
Published: May 28, 2005
The Food and Drug Administration said yesterday that it had received reports of partial vision loss in 38 men taking Viagra, the impotence drug, and among 4 men taking Cialis, a newer competitor.
Wiedereinstieg bei 26 Dollar wäre o.k., ob das noch einmal kommt, ist allerdings fraglich: Der Markt ist bullischer bezüglich Pharma geworden. Außerdem könnte es eine Sommer-Rallye geben, bei der Dip-Buyer, die anderweitig den Zug verpasst haben, PFE als Schnäppchen hochbieten könnten.
EU Verfassung stimmen und der Euro fallen dürfte?
Und die schlechten Nachrichten dürften auch mehr als eingepreist sein bei dem aktuellen Kurs.Gab ja auch nur einen Verhältnismässig kleinen Rücksetzer nach der Viagra Nachricht. Zudem glaube ich das die Leute lieber das Risiko der Erblindung eingehen als auf Viagra zu verzichten, also dürfte eine Erweiterung des Beipackzettels mit dem Warnhinweis Pfizer nicht weiter schaden.
dann ergibt sich das Risiko von 1: 605000 (gerundet). Vernachlaessigbar,
so hat der Markt auch reagiert.
So werden wir die 26 nicht mehr sehen. Meine 1000 Stueck-Order zu $ 25+
wurde nicht ausgefuehrt, weil die Bank kein EMail erhalten hat,
hab's erst nach 10 Tagen erfahren. Wut..... Nicht der erste Fall.
Wenn ich in Deutschland bin suche ich mir einen Broker.
Gruss Jing
Pfizer Agrees to Buy Vicuron for $1.9B
06.16.2005, 08:20 AM
Pfizer Inc., the world's biggest drug maker, agreed on Thursday to acquire Vicuron Pharmaceuticals Inc., a biopharmaceutical company focused on the development of new anti-infection medicines, for $1.9 billion in cash, the companies announced.
Under the merger agreement, Pfizer would purchase outstanding Vicuron stock at $29.10 per share, an 84 percent premium over its closing price on Wednesday and a 74 percent premium to the stock's three-month average closing price.
Vicuron, based in King of Prussia, Pa., develops anti-infectives for both hospital- and community-acquired infections.
The deal gives New York-based Pfizer two products under review for approval by the U.S. Food and Drug Administration: anidulafungin for fungal infections and dalbavancin for skin and soft tissue infections. Sales of Pfizer's anti-fungal Diflucan are down following expiration of its U.S. patent last year.
"This transaction builds on Pfizer's extensive experience in anti-infectives and demonstrates our commitment to strengthen and broaden our pharmaceutical business through strategic product acquisitions," said Hank McKinnell, Pfizer chairman and CEO.
"We are pleased to have a world leader in anti-infective medicines, with a long history of success in the area, introduce these product candidates into the market", said George F. Horner III, president and CEO of Vicuron.
Pfizer and Vicuron already are collaborating and have made significant advances in the discovery of potential next-generation oxazolidinones, the first new class of antibiotics in more than 30 years.
Vicuron had about 60.86 million shares outstanding as of March 31. The deal is expected to close in the third quarter of 2005.
VICURON PHARMACEUTICALS - Nasdaq National Market: MICU
Real-time ECN Quote*
Last Change (%) After Hours Chg (%)** Trade Time Bid Ask
28.23 0.02 (0.07) 0.02 (0.07) 19:29 27.70 (1) 28.50 (10)
At Scottrade, we listen to our customers and have improved the trading technology serving them. Our online trading is fast, accurate and easy to use.
And, online trades are still just $7. Apply now.
Exchange Quote
Last Change (%) Trade Time Bid (size) Ask (size)
28.21 0 (0.00) 0 27.68 (20) 28.01 (20)
Latest Ticks Prev Close Open Low High
28.21 0 0 0
Day Volume Avg Day Vol VWAP 52 Wk Low 52 Wk High
0 213,400 18.7539 8.76 28.23
# of Trades Last Size Avg Trade Size P/E Ratio Market Cap (mil)
0 0 0 65535 1,717
7:28:55 AM EDT - Friday, June 17, 2005- Exchange quote is delayed at least 15 minutes.
Das ist doch auch 'was.
Gruß emarald
Pfizer Gets Lyrica FDA OK for Epilepsy
06.13.2005, 10:55 AM
Drug maker Pfizer Inc. said Monday that the Food and Drug Administration approved Lyrica as an adjunctive treatment of partial onset seizures in adults with epilepsy.
The company said that the approval was based on clinical trials that followed a total of 1,052 patients. Subjects treated in the trials had about 10 seizures a month despite taking one to three other antiepileptic medications. Pfizer said that patients who were also given Lyrica had an up to 51 percent decrease in the frequency of partial seizures.
The FDA approved the drug in December as a treatment for diabetic peripheral neuropathy, a nerve condition caused by diabetes leading to a loss of feeling in the extremities, and postherpetic neuralgia, or nerve damaged caused by shingles.
Lyrica is a type of drug known as an alpha-2-delta ligand that is believed to work by calming hyper-excited neurons.
Pfizer shares rose 2 cents to $27.70 in morning trading on the New York Stock Exchange.
E-mail | Comments | E-Mail Newsletters | RSS
News Headlines | More From Forbes.com | Special Reports
Subscriptions >
§Free Trial Issue of Forbes Forbes Gift Subscription
§Subscribe To Newsletters Subscriber Customer Service
Bei Üfizer tut sich was!
Ob ein Call wohl interessant wäre?
Die Volatilität ist nicht alzu hoch, die Nachrichten und er Chart sehen gut aus!
gruß
gs
Denkbar ist es, dass sich momentan noch einige Käufer finden, die den Kurs hochziehen.
Da sich dieser schon im mittleren Bereich seiner Aufwärtsrange befindet, ist das Kurspotenzial für die nächsten Tage allerdings nicht mehr ganz so groß.
Gruß emarald